Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer

Inclusion Criteria: * Local advanced Rectal cancer: stage T3/4NanyM0 or T1-2N+M0. * Ages: 18 to 75. * No previously received chemotherapy drugs and radiation therapy. * ECOG score: 0 - 2. * Appropriate organ function, as defined below: (Hematology and blood biochemistry examination must be completed within 7 days before the registration date) i) White blood cell count ≥ 4,000/mm3. ii) Neutrophil count ≥ 1,500/mm3. iii) Hemoglobin ≥ 10 g/dL. iv) Platelet count ≥ 100,000/mm3. v) Total bilirubin ≤ 1.5 times the upper limit of normal (ULN). vi. Liver function Index (AST \& ALT) ≤ 1.5 times the upper limit of normal (ULN). vii. Serum creatinine ≤1.5 times the upper limit of normal or creatinine clearance ≥60 ml/min. * Tolerance of orally administration of capecitabine. * Can understand the study, have good compliance, cooperate with follow-up. Exclusion Criteria: * Severe allergic reaction to humanized antibodies or fusion proteins; * Hypersensitivity to any component contained in contrast agent or granule embolic agent; * Diagnosed with an immune deficiency or is receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 14 days prior to the first administration of the study, allowing the use of physiological doses of glucocorticoids (≤10mg/ day of prednisone or equivalent); * Active, known, or suspected autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hypothyroidism, including…